BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230424
DTEND;VALUE=DATE:20230426
DTSTAMP:20260516T055811
CREATED:20230315T103819Z
LAST-MODIFIED:20230315T103819Z
UID:36830-1682294400-1682467199@www.pharmajournalist.com
SUMMARY:10th Annual Pre-Filled Syringes East Coast Conference
DESCRIPTION:10th Annual Pre-Filled Syringes East Coast Conference \nApril 24 – 25\, 2023 \nBoston\, USA \nDriving Innovations in Device Design\, Connectivity and Sustainability for Advanced Parenteral Combination Product \nhttps://www.pfsamericas.com/PJ-Event-listing \nThe 10th annual Pre-Filled Syringes East Coast conference will once again play host to an international audience of drug delivery\, medical device and PFS experts to discuss emerging trends and offer innovative solutions to the challenges facing the pre-filled syringes industry\, helping attendees to secure global success for their devices. \nThe past year has seen significant developments in the injectables landscape with the evolving regulatory landscape\, accelerating opportunities in digitilization and simulation to improve device design efficiency\, and increased opportunities for connectivity to improve the user experience. \nFurthermore\, with a growing need for circular economy\, this year’s conference will assess case studies of sustainable approaches for device packaging and life cycle management\, while panel discussions\, FDA and BioPhorum addresses will evaluate current and upcoming combination product guidelines and the potential for harmonization. \nAs part of SAE Media Group’s leading drug delivery portfolio of events\, this event will bring you the key insights you need to expand and enhance your injectable device portfolio and the opportunity to network with senior players throughout the industry.  \nBenefits of Attending: \n\nDiscover the latest industry developments for improved large volume and high viscous delivery via advanced autoinjector and on body delivery system design\nAssess the growing opportunities of digitalization and simulation for improved device development efficiency and potential\nEngage in an FDA regulatory roundup from the office of combination products\, insights into EPR identification from BioPhorum and a panel discussion assessing harmonization of the regulatory landscape\nDelve into emerging technologies in injectable device design and case studies on digital integration of medical devices for improved user experience\n\nBenchmark against sustainable device packaging case studies driving the combination product industry towards circular economy
URL:https://www.pharmajournalist.com/event/10th-annual-pre-filled-syringes-east-coast-conference/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T055811
CREATED:20230126T191447Z
LAST-MODIFIED:20230126T191447Z
UID:36382-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:Next Generation Cardiovascular Drug Development Summit
DESCRIPTION:Welcome to the Next Generation Cardiovascular Drug Development Summit \nExecuting Cell & Gene Therapy for Cardiac Regeneration \nFollowing technology advancements and the surge of investment in developing the next generation of cardiovascular disease drugs\, the opportunity to successfully leverage our knowledge of CRISPR/Cas9\, siRNA\, autologous iPSC therapy\, capsid engineering\, and digital medicine to reduce the soaring fatality rate has never been closer. \nThe Next Generation Cardiovascular Drug Development Summit in Boston is the only industry-led summit committed to overcoming preclinical challenges to advance your ischemic heart disease\, arrhythmogenic cardiomyopathy\, strokes and hypertension pipelines. \nTo know more visit: https://ter.li/s7qk9l
URL:https://www.pharmajournalist.com/event/next-generation-cardiovascular-drug-development-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T055811
CREATED:20230202T105002Z
LAST-MODIFIED:20230324T110700Z
UID:36448-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Cell Engager Summit
DESCRIPTION:The 5th Annual Cell Engager Summit is back in Boston\, MA this year – the only industry-led meeting bringing together 100+ pharma and biotech leaders will assemble for a 3-day agenda including 4 unique pre-conference workshops to delve into the biggest challenges cell engager therapeutics face. Breaking into the solid tumor\, preventing CRS and maximizing the quality of insights we gain from preclinical modeling. \nFor unmissable opportunities\, including: \n\nGain first-hand knowledge of the difficulties of developing kinase inhibitors to improve selectivity\, cross the blood-brain barrier\, and combat resistance\nUtilize cutting-edge platforms and technologies to maximise target validation and precisely predict off-target impacts to save time and costs\nEstablish long-lasting relationships by speaking with top pharma and biotech firms that are working on kinase inhibitor medicines and looking for the best-in-class solutions directly\n\nJoin your colleagues from the likes of Apexigen\, Regeneron Pharmaceuticals\, Genentech\, Roche\, Amgen\, Boehringer Ingelheim and many more at the most comprehensive cell engager event\, leaving no stone unturned\, this highly focussed meeting covers everything translational and clinical in greater depth and detail than any before it. \nDownload the full event guide for your sneak peek.
URL:https://www.pharmajournalist.com/event/5th-cell-engager-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T055811
CREATED:20230202T110212Z
LAST-MODIFIED:20230202T110212Z
UID:36461-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Neuroimmunology Drug Development Summit
DESCRIPTION:With increasing prioritization for neuroscience discovery\, huge biopharma is investing in expanding its departments\, focusing on glial biology\, neuroinflammatory biomarkers\, and optimizing various approaches to target the likes of LRKK2\, TREM2\, and more. Therefore\, there is a great amount of novel and promising research to be discussed in 2023. \nUniting 100+ neuroinflammation and neuroimmunology experts across all neurological indications\, including AD\, PD\, ALS\, and MS\, the 5th Annual Neuroimmunology Drug Development meeting will return to Boston to host discovery\, preclinical\, translational\, and clinical experts from the likes of Genentech\, Muna Therapeutics\, Biogen\, Janssen\, Bristol Myers Squibb\, Sanofi\, Takeda\, and Roche. \nWith new speakers from the hottest biopharma in neuroimmunology delivering\, a comprehensive program of pioneering and cutting-edge content\, don’t miss your crucial chance to join this niche audience of innovators with a shared desire to explore strategy\, creation\, and implementation of research\, biomarker\, and clinical hypothesis testing in neuroimmunology. \nTo know more visit: https://ter.li/w642sd
URL:https://www.pharmajournalist.com/event/5th-neuroimmunology-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T055811
CREATED:20230207T094958Z
LAST-MODIFIED:20230207T094958Z
UID:36542-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:Gene Therapy Durability Summit
DESCRIPTION:Uniting the leading minds in gene therapy at the Gene Therapy Durability Summit\, join us to: \n\nLeverage knowledge from current clinical trials with relevant durability data across a range of indication types using AAV\nBetter understand what can be extrapolated and how to gain confidence in the data collected\nBuild study designs with durability in mind and explore how well preclinical models have predicted clinical durability to date\n\nHear from the likes of Pfizer\, Selecta Biosciences\, Spark Therapeutics\, Rocket Pharmaceuticals\, ASC Therapeutics and more across a preconference workshop day\, expert presentations\, interactive panel discussions\, dedicated Q&A time and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field. \nWhen you attend you will: \n\nUnderstand the regulatory requirements to determine robust durability\nExplore the challenges short term immunogenicity has on durability\nNavigate how to overcome long term immunogenicity concerns on durability\nOptimize vectors constructs to maximize gene therapy durability\nDiscover how to better predict the translational success of durability when progressing from preclinical to clinical trials\n\nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/oeczu3
URL:https://www.pharmajournalist.com/event/gene-therapy-durability-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T055811
CREATED:20230227T130914Z
LAST-MODIFIED:20230227T130914Z
UID:36686-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:2nd ADC Analytical Development Summit 2023
DESCRIPTION:The 2nd ADC Analytical Development Summit (April 25-27\, 2023 | Boston\, MA) is the only meeting focused on optimizing the application of analytical technologies for ADC\, from drug-linker and drug substance through to drug product to guide regulatory specifications and submissions\, to enhance understanding of your drug and to exert control over your process. \nSee the complete 2023 event guide here. \nWith many new ADCs under development\, the analytical challenges are only increasing as the existing hurdles keep changing\, with the regulatory guidance still being limited. This is a unique touch point for drug developers to discuss the core analytical challenges the industry is facing including drug linkers\, drug substances\, drug formulation\, and drug products. \nYou and your team can expect to leave this meeting equipped to have a deeper understanding of your drug and confidently enter conversations with regulators with thought-provoking insights from our expert speaker faculty including: \n\nYuan Gao\, Head of Analytical Development\, ADC Therapeutics \nJessica Webb\, Scientist\, Analytical Sciences\, AstraZeneca\nGuifeng Jiang\, Head of Analytical Development Pharmaceutical Operation\, Bolt Biotherapeutics\nThomas Gardinier\, Head of Materials Analysis\, Elucida Oncology\nSimon Letarte\, Director\, Gilead\nAdrienne Wildt\, Senior Director of Analytical Development\, ImmunoGen\nShuwen Sun\, Principal Scientist\, Merck & Co\nVimal Patel\, Vice President\, Head of CMC & Supply Chain\, Orum Therapeutics\nJulie Beaudet\, CMC Staff Scientist\, Regeneron Pharmaceuticals\nSarah Owen\, Senior Scientist Potency Assays\, Seagen\nMelvin Flores\, Director Quality Control Analytical & Microbiology\, Sutro Biopharma\nMay Zhu\, Director of Analytical Development- External Interface Management\, Takeda\n\nJoin them here. \nWith 100+ attendees\, 4+ hours of dedicated networking\, and 3 days of exciting new content\, including a pre-conference focus day on comparability studies\, this is a conversation you won’t want to miss to hopefully\, increase knowledge on your ADC quality attributes to understand and strive for regulatory approval
URL:https://www.pharmajournalist.com/event/2nd-adc-analytical-development-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR